Innoviva (INVA)
(Real Time Quote from BATS)
$19.82 USD
+0.08 (0.41%)
Updated Oct 8, 2024 03:42 PM ET
After-Market: $19.84 +0.02 (0.10%) 4:06 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.82 USD
+0.08 (0.41%)
Updated Oct 8, 2024 03:42 PM ET
After-Market: $19.84 +0.02 (0.10%) 4:06 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Zacks News
Innoviva (INVA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Innoviva (INVA) closed the most recent trading day at $14.05, moving -0.07% from the previous trading session.
5 Beaten-Down Biotech Stocks Set to Rebound in 2020
by Kinjel Shah
Here we discuss some biotech stocks, which are down this year so far but have the potential to bounce back next year.
Should Value Investors Buy Innoviva (INVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Mallinckrodt Initiates Phase IV Study on Acthar for Keratitis
by Zacks Equity Research
Mallinckrodt (MNK) initiates phase IV, multi-center, multiple-dose, open-label study to assess the effects of lead drug Acthar Gel as a therapy option in patients with severe keratitis.
Horizon Therapeutics Eye Drug Gets Positive FDA Advisory Vote
by Zacks Equity Research
Horizon Therapeutics' (HZNP) pipeline candidate, teprotumumab, gets favorable vote from DODAC of the FDA for the treatment of Thyroid Eye Disease.
BioCryst Submits NDA for Hereditary Angioedema Candidate
by Zacks Equity Research
BioCryst (BCRX) files a new drug application to the FDA for once-daily berotralstat (BCX7353), which is being developed for the prevention of hereditary angioedema attacks.
VistaGen Up on Fast Track Designation for Anxiety Disorder Drug
by Zacks Equity Research
The FDA assigns a Fast Track status to VistaGen's (VTGN) neuroactive nasal spray PH94B for the on-demand treatment of social anxiety disorder. Stock surges.
TG Therapeutics' Shares Soar on Positive Early-Stage Data
by Zacks Equity Research
TG Therapeutics (TGTX) announces positive first clinical data from its once daily, oral, BTK inhibitor, TG-1701, as a single agent and as a triple therapy in combination.
Top Ranked Value Stocks to Buy for December 10th
by Zacks Equity Research
Here are three stocks with buy rank and strong value characteristics for investors to consider today, December 10th.
Regeneron Reports Initial Data for Multiple Myeloma Drug
by Zacks Equity Research
Regeneron (REGN) reports initial data for REGN5458, a BCMAxCD3 bispecific antibody, in patients with relapsed or refractory (R/R) multiple myeloma.
Top Ranked Value Stocks to Buy for December 9th
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, December 9th
Ra Pharmaceuticals Begins Phase II Study on Autoimmune Drug
by Zacks Equity Research
Ra Pharmaceuticals (RARX) begins dosing of the first patient in its phase II study of zilucoplan for the treatment of immune-mediated necrotizing myopathy.
Top Ranked Value Stocks to Buy for December 3rd
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, December 3rd
Sorrento Turns Down Two All-Cash Takeover Bids, Stock Jumps
by Zacks Equity Research
Sorrento (SRNE) rejects an all-cash unsolicited acquisition proposal from two unknown biopharmaceutical companies. The stock shoots up.
Alexion Gets Approval for Label Expansion of Soliris in Japan
by Zacks Equity Research
Alexion (ALXN) gets Japan Ministry of Health, Labour and Welfare's approval for the label expansion of Soliris.
Surging Earnings Estimates Signal Upside for Innoviva (INVA) Stock
by Zacks Equity Research
Innoviva (INVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Value ETFs & Stocks Offering Real Value: 5 Top Picks
by Sanghamitra Saha
A favorable operating backdrop and cheap valuation are leading value stocks higher. Play the trend with these cheap value stocks and ETFs.
Moleculin Files New Patents for Cancer Candidate Annamycin
by Zacks Equity Research
Moleculin (MBRX) petitions for new patents to cover annamycin, currently being developed for treating patients with relapsed or refractory acute myeloid leukemia. Shares rise.
Celgene (CELG) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Celgene (CELG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cambrex, Innoviva, Celgene, BioDelivery Sciences International and Unity Biotechnology
5 Biotech Stocks to Gain From Trade Deal Rally on the Horizon
by Swarup Gupta
Trade-war resistant stocks such as biotechs would be the first to benefit from a relief rally.
Earnings Estimates Moving Higher for Innoviva (INVA): Time to Buy?
by Zacks Equity Research
Innoviva (INVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
New Strong Buy Stocks for May 15th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
Is Innoviva (INVA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (INVA) Outperforming Other Medical Stocks This Year?
3 Reasons Momentum Stock Investors Will Love Innoviva (INVA)
by Zacks Equity Research
Innoviva (INVA) stock is looking quite impressive for momentum-oriented investors as it has favorable price performance and is also seeing positive estimate revisions.